
Learn how optometrists can best support patients with Parkinson's disease by implementing personalized care protocols tailored to their specific needs.
Parkinson’s disease (PD) is the most common neurodegenerative movement disorder.1 With 90,000 new diagnoses every year in the US, people living with the disease will reach a 1.2 million all-time high by 2030.2
Life expectancy is largely unaffected by PD,3 meaning that most patients live with it, rather than die from it. Eyecare providers (ECPs) have the unique opportunity to significantly improve patient’s quality of life by directly addressing visual manifestations and strengthening treatment efficacy by monitoring disease progression through customized exams and initiating interdisciplinary care.
PD is a progressive disease that directly affects movement, mood, behavior, and sleep. It impacts cognition, impulse control, working memory, learning, attention, motivation, and dreaming. Dopamine is found in the olfactory bulb, midbrain substantia nigra, hypothalamus, ventral tegmental area (VTA), retina, and the periaqueductal gray area and contributes to various body functions and behaviors.4
PD is caused by decreased dopamine production in the brain. In addition, the inhibition of prolactin production is a byproduct of the condition. People with Parkinson’s (PwP) do not experience symptoms until approximately 60 to 80% of the dopamine-producing neurons are lost in the VTA of the substantia nigra.4,5
As represented in Table 1 below, dopamine depletion in PD leads to specific motor and non-motor symptoms.6
| Motor Symptoms | Non-motor Symptoms |
|---|---|
| Resting tremor | Constipation |
| Bradykinesia | Hyposomia |
| Rigidity | Rapid eye movement (REM) sleep behavior disorder |
| Postural instability | Mood disorders |
| Urinary frequency/urgency |
PD can affect multiple aspects of the visual system, but these symptoms are often not readily disclosed by patients and overlooked by healthcare providers.6,7 In one cross-sectional study, 82% of PwP reported one or more ophthalmic symptoms, and 68% revealed they impaired daily activities.11
Below are potential ocular complications of PD and clinical pearls to serve these patients best:
Blinking/lid abnormalities
Blepharitis: Associated with low blink rate and unstable tear film
Blepharospasm
Ocular apraxia: Inability to voluntarily open their eyes, often while speaking
Blurred vision
Multifactorial—PD-related causes may include:
Eye movement problems
Anticholinergic medications
Color and contrast vision problems
Affects 18 to 50% PwP
Due to the depletion of dopamine levels in the retina
Affects approximately 10 to 30% PwP and is multifactorial
Monocular diplopia: Age-related cataracts or dry eye
Binocular diplopia: Binocular disorders or new onset strabismus
Selective diplopia: Rare type of Parkinsonian hallucination
Affects approximately 60% PwP
Due to blink rates as low as 1 to 2 times/min
Related to depleted dopamine levels and associated medications
Eye movement problems
Saccadic dysfunction
Vergence disorders
Palinopsia
Long-lasting high-resolution after-images13
Can be seen minutes, days, or weeks after the original image is seen13
Spatial awareness
Changes in visual processing
Caused by reduced volume of gray matter in visual centers of the brain
Visual hallucinations
Affect 75% PwP as the condition progresses
Customized eye exams for PwP not only evaluate for all ocular diseases (cataracts, glaucoma, retinal abnormalities, etc), but target specific patient needs.
ECPs can easily incorporate tests into their current pretesting and exam routine to identify, monitor, and proactively manage the underlying causes of PD-related ocular symptoms.
Have patients fill out the Visual Impairment in Parkinson’s Disease Questionnaire (VIPD-Q) prior to the exam or with the technician during pretesting. These answers can be used to guide patient history and as a jumping-off point for further discussion.
Include distance and near contrast sensitivity testing in pretesting with the technician (e.g., Mars Letter Contrast Sensitivity Test for distance and Lea Numbers Low-Contrast Flip Chart for near).
Administer color vision testing focusing on blue-yellow abnormalities (e.g., Hardy Rand Rittler [HRR] test).
Perform ocular motility testing, such as vergences, saccades, phorias, and near point of convergence (NPC).
Evaluate the cornea with sodium fluorescein (NAFL) and tear breakup time (TBUT).
Attain anterior segment and retinal photos to monitor changes.
Perform optical coherence tomography (OCT) and OCT angiography (OCTA) to monitor for retinal thinning, as OCT imaging has shown promise in monitoring disease progression,10 and combined OCT/OCTA testing has shown improved diagnostic value when compared to either OCT or OCTA alone.12
A 2020 study found reduced temporal retinal nerve fiber layer (RNFL) thickness, total macular volume (TMV), macular retinal thickness (MRT), and ganglion cell-inner plexiform layer complex (GCL-IPL) thickness via spectral-domain OCT (SD-OCT) testing.12
The same study revealed significantly lower vessel length density (VLD) at the central (1mm diameter around fovea), inner (1 to 3mm diameter around fovea), and full (6mm diameter from the fovea) regions via SD-OCTA.12
Additionally, vessel perfusion density (VPD) in all regions (1mm, 1 to 3mm, 3 to 6mm and 6mm diameter around fovea), and foveal avascular zone (FAZ) circularity index were also significantly lower in PwP when compared to study controls.12
While further studies are needed, these noninvasive procedures will likely become an integral part of PwP care.
Specialized eye exams, enhanced patient engagement, and personalized multi-disciplinary care are imperative to the successful ocular management of PwP.
Primary eyecare providers can substantially improve the quality of life by maximizing patient independence and playing a vital role in delivering the best care possible for these patients.